Givinostat

CAS No. 732302-99-7

Givinostat ( ITF2357 )

Catalog No. M15799 CAS No. 732302-99-7

Givinostat hydrochloride monohydrate is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 65 In Stock
10MG 115 In Stock
25MG 228 In Stock
50MG 417 In Stock
100MG 615 In Stock
500MG 1305 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Givinostat
  • Note
    Research use only, not for human use.
  • Brief Description
    Givinostat hydrochloride monohydrate is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.
  • Description
    Givinostat hydrochloride monohydrate is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.
  • Synonyms
    ITF2357
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    HDAC
  • Recptor
    HD1-A; HD1-B; HD2
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    732302-99-7
  • Formula Weight
    475.97
  • Molecular Formula
    CHClNO
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO:95 mg/mL (199.59 mM); Ethanol:3 mg/mL (6.3 mM); Water:<1 mg/mL (<1 mM)
  • SMILES
    O=C(OCC1=CC=C2C=C(CN(CC)CC)C=CC2=C1)NC3=CC=C(C(NO)=O)C=C3.[H]Cl.O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78.
molnova catalog
related products
  • Encorafenib

    LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

  • MPI_5a

    MPI_5a is an effective and selective inhibitor of HDAC6 (IC50=36 nM).

  • EDO-S101

    EDO-S101 (Tinostamustine)is a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat.